{
    "id": 25923,
    "fullName": "PLCG2 L845F",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PLCG2 L845F does not lie within any known functional domains of the Plcg2 protein (UniProt.org). L845F confers a gain of function to Plcg2, as indicated by increased basal activity and enhanced sensitivity to Rac and Vav1 stimulation in culture, and is associated with resistance to Btk inhibition (PMID: 27542411).",
            "references": [
                {
                    "id": 7583,
                    "pubMedId": 27542411,
                    "title": "The Phospholipase C\u03b32 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27542411"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5336,
        "geneSymbol": "PLCG2",
        "terms": [
            "PLCG2",
            "APLAID",
            "FCAS3",
            "PLC-gamma-2",
            "PLC-IV"
        ]
    },
    "variant": "L845F",
    "createDate": "01/17/2017",
    "updateDate": "06/30/2018",
    "referenceTranscriptCoordinates": {
        "id": 101878,
        "transcript": "NM_002661",
        "gDna": "chr16:g.81928578A>T",
        "cDna": "c.2535A>T",
        "protein": "p.L845F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9767,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, treatment with EHT 1864 decreased Plcg2 activity in cells expressing PLCG2 L845F in culture, suggesting that Rac inhibition may be a potential treatment approach for tumors harboring Imbruvica (ibrutinib)-resistant PLCG2 mutations (PMID: 27542411).",
            "molecularProfile": {
                "id": 27057,
                "profileName": "PLCG2 L845F"
            },
            "therapy": {
                "id": 5223,
                "therapyName": "EHT 1864",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7583,
                    "pubMedId": 27542411,
                    "title": "The Phospholipase C\u03b32 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27542411"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9766,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PLCG2 L845W was identified as a potential resistance mechanism in a chronic lymphocytic leukemia patient that relapsed on Imbruvica (ibrutinib), which was supported by culture experiments demonstrating cells expressing PLCG2 L845W had decreased sensitivity to Imbruvica (ibrutinib) following antibody stimulation (PMID: 24869598).",
            "molecularProfile": {
                "id": 27057,
                "profileName": "PLCG2 L845F"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 964,
                    "pubMedId": 24869598,
                    "title": "Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24869598"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27057,
            "profileName": "PLCG2 L845F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 101878,
            "transcript": "NM_002661",
            "gDna": "chr16:g.81928578A>T",
            "cDna": "c.2535A>T",
            "protein": "p.L845F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}